Cite
MLA Citation
Luc-Matthieu Fornecker et al.. “Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.” Journal of clinical oncology, vol. 41, no. 2, 2023, pp. 327–335. http://access.bl.uk/ark:/81055/vdc_100174260717.0x000004